Dual Injection ESPB Versus Single Injection ESPB for Laparotomies

NCT ID: NCT05633329

Last Updated: 2023-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-07

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate and compare the efficacy of single level injection erector spinae plane block versus double level injection Erector spinae plane block in laparotomies

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Operative Pain Regional Block

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

single ESPB

single injection at level T8

Group Type EXPERIMENTAL

single level

Intervention Type PROCEDURE

injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)

dual ESB

dual injection at level T7 and T9

Group Type EXPERIMENTAL

dual level

Intervention Type PROCEDURE

injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

single level

injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)

Intervention Type PROCEDURE

dual level

injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age18-60.
2. Both genders.
3. abdominal surgery.
4. ASA I-III.

Exclusion Criteria

1. Drug allergy.
2. Morbid obesity (BMI \>40 kg/m2).
3. Psychiatric disorder.
4. Opiod dependence.
5. patient refuse.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Minia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hassan Mokhtar Elshorbagy Hetta

lecturer of anesthesia and ICU

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

hassan m. hetta, lecturer

Role: PRINCIPAL_INVESTIGATOR

Minia University, faculty of medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Minia University

Minya, Minya Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

474:10/2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.